

/ / ()
/ / , ,

*

;
.
() :
.
Natingham Modification Bloom – Richardson ()
.
% / % / :
% / : *Grade III* ,
% / : *Grade I* :

(EGFR)

.() -
.(-)
(in situ)

(Cross-Sectional)

(chronological)

(MIBI/Ki67/TU)

(EGFR/cer B2/neu)

(P53/c-myc/cyclis)

(CD

PS2

(nm23

)

.(-)

Epidermal Growth Factor Receptor

EGFR . (EGFR)

TGF- α EGF

EGFR .

- PBS

PBS

H2O2 %

PBS

.(-)

q

c-ERBB

.(-)

EGFR

EGFR		Natingham Modification of Bloom-Richardson	
(OR = / P = /)		.(-)	
(Grade)		EGFR	
		() EGFR	
/ /		.() () () ()	
/ /			
/			
EGFR		SPSS 10.0 (SPSS, Chicago, USA)	
(%) (%)			
EGFR			
(/) (/) (/)			
(/) (/) (/)			
() (/) (/)			
% /		/ ± /	
% /			
% / ()		()	
% /		% /	
:			
(-) () ()		% /	
% / (-) (-)			
% / % / % /		/ ± /	
% /			
EGFR		EGFR	
		EGFR % /	
		% /	

	EGFR	%	EGFR
	()	.	% EGFR
			GFR
			() % -
EGFR			
	EGFR		
		% /	
	% /		EGFR
EGFR			EGFR
()	Seshardi		
	() Tolgay ocal		
EGFR	Tsutsui	EGFR	J.F. Fernandezval
		Toi M	() % /
	(Disease free survival)	Tsutsui	() %
			() % /
		EGFR	
		(-)	
			EGFR
	EGFR		
		EGFR	
EGFR			
		EGFR	
		EGFR	
		Pirinen	

REFERENCES

1. Kumar V, Cotran R, Robbins S. Basic Pathology. 6th ed. Philadelphia: WB Saunders Company. 1997.
2. Stenberg SS. Diagnostic Surgical Pathology. 3rd ed. Philadelphia: Williams and Wilkms. 1999.
3. Decherney AH, Nathan L. Current obstetric and gynecologic diagnosis and treatment. 9th ed. New York: Lange MCGraw- Hill.2003.
4. Berek JS. Novak's Gynecology. 13th ed. Philadelphia: Williams and Wilkins.2007.
5. Speroff L, Fritz MA. Clinical Gynecologic EndocrMiology and Infertility.7th ed. Philadelphia: Williams and Wilkms. 2005.
6. Donegan WL. Tumor-related prognostic factors for breast cancer. Cancer J Clin 1997; 47: 28-51.
7. Val H, Losada J, Murua MA, Sarria R. Cell proliferation, nuclear ploidy, and EGFR and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma . Cancer Genet Cytogenet 2002;138(1):69-72.
8. Tol M, Osaki A, Yamada H, Toge T. EGM expression as a prognostic indicator in breast cancer. Eur J Cancer 1991; 27(8): 977-80.
9. Tsutui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of EGFR and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Research and Treatment 2002; 71: 67-75.
10. Pirmien R, Lipponen P, Syrianen K. Expression of EGFR in breast cancer as related to clinical, prognostic and cytometric factors. Anticancer Res 1995; 15(68): 2835-40.
11. Seshardri R, McLeay WR, Horsfall W, McCaul K. Prospective study of the prognostic significance of EGFR in primary breast cancer. Int J Cancer 1996; 69(1):23-7.
12. Ocal IT, Dolled-filhart M, Aquila TG, Camp RL, Rimm DL. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that Met expression is associated with worse outcome but is not correlated with EGFR family receptors. Am Cancer Soc 2003; 97(9):1841-8.
13. Kirkegaard T, McGlynn LM, Campbell FM, Müller S, Tovey SM, Dunne B, et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 2007; 13(5):1405-11.
14. Riedemann J, Sohail M, Macaulay VM. Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells. Biochem Biophys Res Commun 2007; 15: 230-3.
15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med. 2007 1; 131(1):18.
16. Fuchs IB, Siemer I, Buhler H, Schmider A. Epidermal growth factor receptor changes during breast cancer metastasis. Anticancer Res 2006; 26(6B):4397-401.

17. Johnston JB, Navaratnam S, Pitz MW. Targeting the EGFR pathway for cancer therapy. *Curr Med Chem*. 2006; 13(29): 3483-92.
18. Homaei-Shandiz F, Ghavam-Nassiri MR, Sharifi N, Homaei-Shandiz AH, Taghizadeh-Kermani A, et al. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer. *Saudi Med J* 2006; 27(12): 1810-4.